OP002: Epigenetic biomarkers to detect UC associated neoplasia: Results from phase I of the ENDCAP-C studyECCO'17 Barcelona 2017
1
OP003: Increased risk of acute arterial events in young patients with severely active Inflammatory Bowel Disease: A nationwide French cohort studyECCO'17 Barcelona 2017
1
OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn‘s DiseaseECCO'17 Barcelona 2017
1
OP005: The PROSIT cohort of infliximab biosimilar in IBD: A prolonged follow-up on the efficacy and safety across ItalyECCO'17 Barcelona 2017
1
OP006: Correlation of durability of response, serum trough concentrations and outcome parameters: Long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trialECCO'17 Barcelona 2017
1
OP007: A multi-centre double blind randomised placebo-controlled study of the use of rectal tacrolimus in the treatment of resistant ulcerative proctitisECCO'17 Barcelona 2017
1
OP009: Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn’s Disease: 52-week results of a phase III randomised controlled trialECCO'17 Barcelona 2017
1
OP010: Long term efficacy and safety of Ustekinumab for Crohn’s Disease: Results from IM-UNITI long-term extension through 2 yearsECCO'17 Barcelona 2017
1
OP011:Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY studyECCO'17 Barcelona 2017
1
OP012: Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with Ulcerative Colitis undergoing (procto)colectomy with ileal pouch- anal anastomosisECCO'17 Barcelona 2017
1
OP013: Disease management and outcomes of patients with Crohn’s Disease at high risk of recurrence. Results from PRACTICROHN studyECCO'17 Barcelona 2017
1
OP014: Histological remission is predictive of improved clinical outcomes in patients with Ulcerative Colitis: Results from the TOUCHSTONE OLEECCO'17 Barcelona 2017
1
OP015: Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn’s Disease: THE LIR!C TRIALECCO'17 Barcelona 2017
1
OP017: Telemedicine enables a safe shift from examination room based care to personalised care for Inflammatory Bowel Disease: A pragmatic randomised multicenter trial with myIBDcoachECCO'17 Barcelona 2017
1
OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn’s Disease treated with mongersen (GED- 0301)ECCO'17 Barcelona 2017
1